The patent covers all compositions of matter and methods of use for NVC-612 and related compounds.
NovaBay said that the new patent will broaden protection for NovaBay’s Aganocide family of compounds and also complements its existing collection of more than 20 patents and pending patent applications on its proprietary technology platforms.
The Aganocide compounds are new, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body’s natural defense against infection.
Mark Anderson, chief scientific officer of NovaBay, said: “This latest patent will further protect NovaBay’s intellectual property, as the company expands its pipeline of non-antibiotic anti-infectives to address additional indications.
“NovaBay’s Aganocide compounds for treating non-systemic, topical infections are designed to rapidly fight infection without causing drug-resistance. This is increasingly important as resistance to antibiotics is becoming a growing public health concern worldwide.”